Organogenesis Holdings Inc. has secured a $130 million private placement deal with Avista Healthcare Partners to bolster its strategic growth, repay debt, and repurchase shares. This investment, ...
Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchasesCANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ...
Organogenesis is a regenerative medicine company with an advanced wound care niche, and it's looking to take over a ...
Reports Q3 revenue $115.2M, consensus $108.83M.”Our third quarter results underscore the strength of our portfolio and brand equity as ...
The Rhode Island Commerce Corporation is scheduled to meet on Thursday morning to consider millions of dollars in incentives ...
Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025.
As the U.S. stock market navigates the uncertainty surrounding the presidential election and upcoming Federal Reserve interest rate decisions, investors are keeping a close eye on various sectors for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback